This is a preview of subscription content, log in via an institution to check access.
References
Ng YS, Turnbull DM (2016) Mitochondrial disease: genetics and management. J Neurol 263(1):179–191
Weisfeld-Adams JD, Katz Sand IB, Honce JM et al (2015) Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis. Brain 138:517–539
Kovács GG, Höftberger R, Majtényi K et al (2005) Neuropathology of white matter disease in Leber’s hereditary optic neuropathy. Brain 128:35–41
Campbell GR, Ziabreva I, Reeve AK et al (2011) Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann Neurol 69(3):481–492
Dutta R, McDonough J, Yin X et al (2006) Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 59(3):478–489
Slee M, Finkemeyer J, Krupa M et al (2011) A novel mitochondrial DNA deletion producing progressive external ophthalmoplegia associated with multiple sclerosis. J Clin Neurosci 18:1318–1324
Krishnan KJ, Reeve AK, Samuels DC et al (2008) What causes mitochondrial DNA deletions in human cells? Nat Genet 40(3):275–279
MITOMAP: a human mitochondrial genome database (2015). http://www.mitomap.org. Accessed 24 Nov 2015
Stys PK, Zamponi GW, Van Minnen J et al (2012) Will the real multiple sclerosis please stand up? Nat Rev Neurosci 13:507–514
Lassmann H, Van Horssen J, Mahad D (2012) Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 8:647–656
Campbell GR, Reeve AK, Ziabreva I et al (2013) No excess of mitochondrial DNA deletions within muscle in progressive multiple sclerosis. Mult Scler 19(14):1858–1866
Acknowledgments
We thank Dr. Paolo Prontera for critically reading the manuscript and for the useful suggestions.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
LG received travel grants from Biogen-Idec, Biogen, Novartis, Teva, Genzyme and Almirall to attend national and international conferences. MDF participated to advisory boards of Biogen Idec, Teva and Bayer, received travel grants from Bayer Schering, Biogen-Dompé, Biogen-Idec, Merck-Serono, Novartis and Sanofi-Aventis to attend national and international conferences and speaker and writing honoraria from Biogen Idec, Novartis and Sanofi-Genzyme. PC received/receive research support from Bayer Schering, Biogen-Dompé, Boehringer Ingelheim, Eisai, Lundbeck, Merck-Serono, Novartis, Sanofi-Aventis, Sigma-Tau and UCB Pharma. He also receives/received support from Ricerca Corrente IRCCS, Ricerca Finalizzata IRCCS, European Community Grant REPLACES (restorative plasticity at corticostriatal excitatory synapses), the Italian Minister of Health, and AIFA (Agenzia Italiana del Farmaco). AMi, MDG, PS, AMa, EC and MTD report no conflicts of interests.
Ethical standards
The authors declare that they have complied with ethical standards.
Informed Consent
Patient consent for publication was obtained.
Additional information
L. Gaetani and A. Mignarri equally contributed to the work.
Rights and permissions
About this article
Cite this article
Gaetani, L., Mignarri, A., Di Gregorio, M. et al. Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion. J Neurol 263, 1449–1451 (2016). https://doi.org/10.1007/s00415-016-8120-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-016-8120-5